Neuron23

About Neuron23

Neuron23 Inc. is a clinical-stage biotechnology company focused on developing precision medicines for Parkinson’s disease driven by hyperactive LRRK2. Neuron23 combines advances in human genetics with a state-of-the-art drug discovery and biomarker platform, leveraging advanced techniques in machine learning and artificial intelligence to advance therapeutics aimed at impacting disease progression. The company’s focus is on transforming the future of treatment for PD through innovation, collaboration, and dedication to enhancing patient outcomes. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA.